A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults
Public ClinicalTrials.gov record NCT07768345. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 3, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF REVACCINATION WITH RESPIRATORY SYNCYTIAL VIRUS STABILIZED PREFUSION F SUBUNIT VACCINE (RSVPREF) IN IMMUNOCOMPROMISED ADULTS
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this phase 3 study is to learn the safety, tolerability and immunogenicity of revaccination with RSVpreF at approximately 1-, 2-, and 3-year intervals to inform the revaccination interval in immunocompromised adults. This study is seeking participants who are 18 years of age and older and will be grouped based on prior RSV vaccination history. Participants are required to be immunocompromised per study protocol. All participants in this study will receive 1 shot to their arm of a RSVPreF vaccine. Participants will take part in this study for about 12 months and will need to visit the clinical study site at least 4 times.
Study identification
- NCT ID
- NCT07768345
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 440 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 30, 2026
- Primary completion
- Feb 1, 2028
- Completion
- Feb 1, 2028
- Last update posted
- Aug 16, 2026
2026 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rochester Clinical Research | Rochester | New York | 14609 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Respiratory Syncytial Virus (RSV) trials
Other public records listing Respiratory Syncytial Virus (RSV). Sorted by last update posted; newest first. Not a recommendation.
- NCT07673081: Real-World Effectiveness of RSV Vaccines Among Adults Using Target Trial Emulation in Epic Cosmos Active, not recruiting
- NCT07249320: Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants Active, not recruiting
- NCT05443607: Transplacental Transmission of RSV (TTRSV) Active, not recruiting
- NCT06564194: A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV Active, not recruiting
- NCT07185399: Systems Biological Analysis of Immune Responses to RSV Vaccine Active, not recruiting
- NCT07050732: Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07768345, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 16, 2026 · Synced Aug 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07768345 live on ClinicalTrials.gov.